Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTAIN-HYPERTENSION: orforglipron once daily in adults with hypertension and overweight or obesity
CTR20252485Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of orforglipron in hypertension (HTN), obesity, Overweight, sponsored by Eli Lilly and Company. Started May 2025; status: active.
02
Drugs
orforglipron
03
Conditions
hypertension (HTN)obesityOverweight
Beyond the preview
Go deeper on CTR20252485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252485.